RxDoctor Payments Data

Robert Bierman, MD

Internal Medicine · Scottsdale, AZNPI 1124023205

Payments from drug & device makers

$1,376in general payments, 2019–2025

Across 18 payments — averaging $76.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi US Services Inc.$325
  • AstraZeneca$218
  • Johnson & Johnson$129
  • Otsuka America Pharmaceutical, Inc.$119
  • Amgen$115
  • Lupin Inc.$103
  • plus $368 from 7 others

What the payments were for

  • Speaking & faculty fees$32524%
  • Food & beverage$1,04676%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,376 in reported general payments places this provider in the 80th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$161,261
Medicare patients
556
Services billed
2,287

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban156$196,900
JardianceEmpagliflozin179$186,129
OzempicSemaglutide119$134,772
XareltoRivaroxaban73$75,809
FarxigaDapagliflozin Propanediol78$63,395
MounjaroTirzepatide49$61,956
ProliaDenosumab35$60,377
JanuviaSitagliptin Phosphate37$47,954
TrulicityDulaglutide27$37,383
Bydureon BciseExenatide Microspheres33$27,501
MyrbetriqMirabegron33$26,167
JanumetSitagliptin Phos/Metformin Hcl27$25,906
LinzessLinaclotide25$22,482
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$22,286
RybelsusSemaglutide11$20,167

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$42$196,900156 claims
Novo NordiskOzempic, Rybelsus$99$154,940130 claims
Johnson & JohnsonXarelto, Invokana$129$91,74893 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$218$75,522110 claims
AmgenProlia$115$60,37735 claims
GSKTrelegy Ellipta, Anoro Ellipta$63$27,15738 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →